




# **MO HEALTHNET PHARMACY PROGRAM AND BUDGET UPDATE**

**MHD DRUG PA COMMITTEE MARCH 19, 2020  
JOSH MOORE, PHARM D-DIRECTOR OF PHARMACY**


# Eligibles by Group January 2020

Total Eligibles 846,063




# Expenditures by Enrollment Group: July 2019-Jan 2020

Total Spend \$764,663,755




# JULY 2019-JAN 2020 MO HEALTHNET EXPENDITURES BY SERVICE



# FY20 Pharmacy Spend vs Total Medicaid Spend

Total Spend \$5,466,727,210

July 2019-Jan 2020




# Prior Authorization and DUR Committee Class Reviews

**Pharmacy Reimbursement for Calendar Year 2019 for classes reviewed during March/April meetings:**

**Medications in Clinical and Fiscal Edits: \$14,948,594.92**


**Medications in Preferred Drug Lists: \$160,404,800**

**Total: \$175,353,394.92**



# Pharmacy Expenditures FY20

## July 2019-March 2020




# PHARMACY PROGRAM

## TOP 4 DRUG CLASSES PER FY

<b>HICL Description</b>	<b>FY 2017</b>
LURASIDONE HCL (Latuda)	\$34,874,852
PALIPERIDONE PALMITATE (Invega)	\$29,395,238
ALBUTEROL SULFATE	\$26,081,437
METHYLPHENIDATE HCL (ADHD)	\$25,333,080
<b>HICL Description</b>	<b>FY 2018</b>
PALIPERIDONE PALMITATE (Invega)	\$36,914,022
LURASIDONE HCL (Latuda)	\$36,192,993
ADALIMUMAB (Humira)	\$28,797,827
METHYLPHENIDATE HCL (ADHD)	\$27,321,955
<b>HICL Description</b>	<b>FY 2019</b>
PALIPERIDONE PALMITATE (Invega)	\$40,792,733
LURASIDONE HCL (Latuda)	\$37,240,789
ADALIMUMAB (Humira)	\$30,733,203
ANTIHEMOPHILIC FACTOR(FVIII)RECOMBINANT	\$25,767,689
<b>HICL Description</b>	<b>FYTD 2020</b>
PALIPERIDONE PALMITATE (Invega)	\$36,602,796
LURASIDONE HCL (Latuda)	\$27,666,757
ADALIMUMAB (Humira)	\$26,774,204
METHYLPHENIDATE HCL (ADHD)	\$21,072,133



# JULY 2019-March 2020 MO HEALTHNET RARE DISEASE EXPENDITURES



# Tamiflu Claim Count

